Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.

abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

journal_title：Diabetes technology & therapeutics

authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

更新日期：2017-01-01 00:00:00

abstract：AIM:This study explored the role of glycemic control on cardiac autonomic function, measured by heart rate variability (HRV), in youth with type 1 diabetes. PATIENTS AND METHODS:A retrospective cohort of 345 youth with type 1 diabetes (mean age, 18.5 years; duration, 10 years) participating in the SEARCH for Diabetes ...

journal_title：Diabetes technology & therapeutics

authors： Jaiswal M,Fingerlin TE,Urbina EM,Wadwa RP,Talton JW,D'Agostino RB Jr,Hamman RF,Daniels SR,Marcovina SM,Dolan LM,Dabelea D

更新日期：2013-12-01 00:00:00

abstract：: Background: Continuous glucose monitoring (CGM) systems are widely and increasingly used in diabetes self-management and in the context of clinic visits. However, access to CGM data during visits can be challenging. Clinic inefficiencies can restrict the time available for...

journal_title：Diabetes technology & therapeutics

authors： Espinoza J,Shah P,Raymond J

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and...

journal_title：Diabetes technology & therapeutics

authors： Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Skin autofluorescence (AF) as measured with the AGE Reader (DiagnOptics Technologies, Groningen, The Netherlands) is a noninvasive prognostic marker in diabetes mellitus and other diseases with increased cardiovascular risk. This study provides reference values of healthy Caucasian control subjects as a func...

journal_title：Diabetes technology & therapeutics

authors： Koetsier M,Lutgers HL,de Jonge C,Links TP,Smit AJ,Graaff R

更新日期：2010-05-01 00:00:00

abstract：BACKGROUND:Internet technology has been proven to be a successful tool for the management of patients with multiple medical conditions. The purpose of this study was to demonstrate the feasibility of monitoring glucose control in indigent women with gestational diabetes mellitus (GDM) over the Internet. METHODS:Women ...

journal_title：Diabetes technology & therapeutics

authors： Homko CJ,Santamore WP,Whiteman V,Bower M,Berger P,Geifman-Holtzman O,Bove AA

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen in autoimmune diabetes and is discharged from injured islet beta cells. GAD65 may also be released by transplanted islets undergoing immunological rejection. To test hypotheses regarding the utility of GAD65 as a biomarker for transplant rejection...

journal_title：Diabetes technology & therapeutics

authors： Waldrop MA,Suckow AT,Hall TR,Hampe CS,Marcovina SM,Chessler SD

更新日期：2006-04-01 00:00:00

abstract：BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

journal_title：Diabetes technology & therapeutics

authors： Albisser AM,Sakkal S,Wright C

更新日期：2005-06-01 00:00:00

abstract：:Most previous attempts at the development of a "smart tattoo" for glucose monitoring in diabetes--implantable fluorescent microspheres that can be implanted intradermally and interrogated transdermally using light--have focused on the encapsulation of a competitive binding assay for glucose within hydrogel microsphere...

journal_title：Diabetes technology & therapeutics

authors： Brown JQ,Srivastava R,Zhu H,McShane MJ

更新日期：2006-06-01 00:00:00

abstract：:Continuous glucose monitoring (CGM) is a new tool that has recently become available to people with diabetes. Properly designing and conducting trials in order to answer important questions regarding the clinical usefulness of CGM is very difficult and fraught with many confounding variables and unique challenges. Ini...

journal_title：Diabetes technology & therapeutics

authors： Edelman SV,Bailey TS

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may...

journal_title：Diabetes technology & therapeutics

authors： Clements M,Matuleviciene V,Attvall S,Ekelund M,Pivodic A,Dahlqvist S,Fahlén M,Haraldsson B,Lind M

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:During the proteomic era, one of the most rapidly growing areas in biomedical research is biomarker discovery, particularly using proteomic technologies. The urinary proteome is known to be a valuable field of study and has become one of the most attractive subdisciplines in clinical proteomics for human dis...

journal_title：Diabetes technology & therapeutics

authors： Riaz S,Alam SS,Srai SK,Skinner V,Riaz A,Akhtar MW

更新日期：2010-12-01 00:00:00

abstract：OBJECTIVE:This study assessed the accuracy and reliability of three continuous glucose monitoring (CGM) systems. RESEARCH DESIGN AND METHODS:We studied the Animas® (West Chester, PA) Vibe™ with Dexcom® (San Diego, CA) G4™ version A sensor (G4A), the Abbott Diabetes Care (Alameda, CA) Freestyle® Navigator I (NAV), and ...

journal_title：Diabetes technology & therapeutics

authors： Luijf YM,Mader JK,Doll W,Pieber T,Farret A,Place J,Renard E,Bruttomesso D,Filippi A,Avogaro A,Arnolds S,Benesch C,Heinemann L,DeVries JH,AP@home consortium.

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This stu...

journal_title：Diabetes technology & therapeutics

authors： Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

journal_title：Diabetes technology & therapeutics

authors： Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

更新日期：2005-02-01 00:00:00

abstract：: Background: The prevalence of diabetes in youth is increasing worldwide in parallel with the obesity epidemic. This study aimed to determine the incidence rates of dysglycemia (diabetes or prediabetes) and evaluate the predictors of its progression or regression to normal ...

journal_title：Diabetes technology & therapeutics

authors： Mehreen TS,Kamalesh R,Pandiyan D,Kumar DS,Anjana RM,Mohan V,Ranjani H

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can int...

journal_title：Diabetes technology & therapeutics

authors： Deshpande S,Pinsker JE,Zavitsanou S,Shi D,Tompot R,Church MM,Andre C,Doyle FJ 3rd,Dassau E

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:This article reports a prolonged trial with insulin pumps implanted in patients with type 1 diabetes showing poor glucose control and a high rate of complications. METHODS:We reviewed data from 181 patients undergoing implanted insulin pump therapy. Analysis included hemoglobin A1c (HbA1c) values, body weig...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Renard E,Jeandidier N,Hanaire H,Fermon C,Rudoni S,Catargi B,Riveline JP,Guerci B,Millot L,Martin JF,Sola A,EVADIAC Group.

更新日期：2011-06-01 00:00:00

abstract：:Continuous glucose monitoring (CGM) systems have been available for more than 15 years by now. However, market uptake is relatively low in most countries; in other words, relatively few patients with diabetes use CGM systems regularly. One major reason for the reluctance of patients to use CGM systems is the costs ass...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,DeVries JH

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize ...

journal_title：Diabetes technology & therapeutics

authors： Park C,Le QA

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

journal_title：Diabetes technology & therapeutics

authors： Whitelaw BC,Choudhary P,Hopkins D

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Patients undergoing intensive insulin therapy may have blood glucose (BG) samples drawn from arterial, capillary, or venous sources. This study compared capillary and venous BG across a range of glucose concentrations and under conditions of rapid change in BG. METHODS:Following a 10-h fast, 40 adult patien...

journal_title：Diabetes technology & therapeutics

authors： Kempe K,Price D,Ellison J,Marhoul J,Morrow L,Win K,Kuschma K,Hompesch M

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:To protect against ischemia, pressure-induced vasodilation (PIV) causes an increase in skin blood flow. Endothelial dysfunction, which is commonly found in older patients and those with diabetes, and global temperatures can affect the resting blood flow in skin, which may reduce the blood flow during and aft...

journal_title：Diabetes technology & therapeutics

authors： McLellan K,Petrofsky JS,Zimmerman G,Lohman E,Prowse M,Schwab E,Lee S

更新日期：2009-12-01 00:00:00

abstract：: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

journal_title：Diabetes technology & therapeutics

authors： Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

更新日期：2020-03-01 00:00:00

abstract：:There are three main issues in non-invasive (NI) glucose measurements: namely, specificity, compartmentalization of glucose values, and calibration. There has been progress in the use of near-infrared and mid-infrared spectroscopy. Recently new glucose measurement methods have been developed, exploiting the effect of ...

journal_title：Diabetes technology & therapeutics

authors： Khalil OS

更新日期：2004-10-01 00:00:00

abstract：:Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

journal_title：Diabetes technology & therapeutics

authors： Kendall DM,Kim D,Maggs D

更新日期：2006-06-01 00:00:00

abstract：:Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes. However, the progressive nature of the disease means that some individuals may require additional ways to maintain their glycemic goals. Intensification in these circumstances ha...

journal_title：Diabetes technology & therapeutics

authors： Perfetti R

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) technologies report measurements of interstitial glucose concentration every 5 min. CGM technologies have the potential to be utilized for prediction of prospective glucose concentrations with subsequent optimization of glycemic control. This article outlines a feed-forwar...

journal_title：Diabetes technology & therapeutics

authors： Pappada SM,Cameron BD,Rosman PM,Bourey RE,Papadimos TJ,Olorunto W,Borst MJ

更新日期：2011-02-01 00:00:00

abstract：:Maintaining optimal blood glucose (BG) control is difficult for type 1 diabetes mellitus (T1DM) patients when typical daily regimens of food, insulin and exercise are altered. Artificial intelligence (AI) systems consisting of treatment algorithms calibrated through large datasets of patient specific information may o...

journal_title：Diabetes technology & therapeutics

authors： Otto E,Semotok C,Andrysek J,Basir O

更新日期：2000-01-01 00:00:00